New trabecular MIGS device shows promise in treating glaucoma

The iStent infinite trabecular micro-bypass device, used either alone or in conjunction with other procedures like goniotomy, demonstrates promising efficacy in reducing intraocular pressure (IOP) and medication burden in patients with open-angle glaucoma who have previously undergone unsuccessful laser trabeculoplasty, according to a poster presented at ASCRS 2024. The study found significant reductions in both IOP and medication usage over a 6-month follow-up period, with no reported intraoperative complications or postoperative adverse events.

The study examined 14 eyes of 9 patients with mild to severe open-angle glaucoma. All participants were pseudophakic and had undergone at least one unsuccessful laser trabeculoplasty procedure in the past. Under the care of a single surgeon, all patients received successful implantation of 3 iStent infinite stents, with no intraoperative complications reported.

Furthermore, in 36% of the eyes, an additional goniotomy procedure using the iAccess Precision Blade was performed. The results indicated a promising outcome, with a mean reduction in IOP from 21.6 ± 3.0 mmHg preoperatively to 16.8 ± 2.6 mmHg at the 6-month follow-up mark, translating to a 22% decrease (P = 0.135). Additionally, there was a significant reduction in the mean number of medications required, dropping from 1.1 ± 0.4 preoperatively to 0.2 ± 0.4 at the 6-month interval, marking an 82% decrease (P = 0.013). No postoperative adverse events or secondary surgeries were recorded during the follow-up period.

Reference

Benson CE. Early Outcomes after Third-Generation Trabecular Micro-Bypass with/without Goniotomy in Eyes with Failed Prior Glaucoma Intervention. Poster presented at: ASCRS Annual Meeting 2024.